Monoclonal antibody - Xencor/Boehringer Ingelheim

Drug Profile

Monoclonal antibody - Xencor/Boehringer Ingelheim

Latest Information Update: 20 Sep 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim; Xencor
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 06 Sep 2016 Phase-I clinical trials in Cancer in USA (Parenteral) before September 2016 (Xencor pipeline, September 2016)
  • 04 Apr 2012 Xencor receives second milestone payment from Boehringer Ingelheim
  • 13 Oct 2010 Boehringer Ingelheim files for regulatory approval for phase I clinical trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top